Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk (NVO) Announces Positive Obesity Program Data
02:39pm, Tuesday, 23'rd May 2023
Novo Nordisk's (NVO) late-stage study of once-daily oral semaglutide 25 mg and 50 mg in obesity shows superior weight loss at week 68 compared with placebo.
Why Novo Nordisk Stock Is Falling Today
02:06pm, Tuesday, 23'rd May 2023
Yesterday, Pfizer published strong mid-stage trial data for its diabetes and weight-loss candidate, danuglipron. This development may spell bad news for Novo Nordisk's flagship medication, semaglutide
Novo Nordisk: Flourishing Financials And Emerging Opportunities In Diabetes And Obesity
11:40am, Tuesday, 23'rd May 2023
Novo Nordisk showed substantial Q1 2023 growth, with a 27% rise in net sales and a 39% boost in net profit. Diabetes and obesity care sales notably increased. The firm's solid capital structure, boast
The Important — And Overlooked — Caveat Behind Pfizer's Rival To Novo Nordisk In Diabetes
10:43am, Tuesday, 23'rd May 2023
It's the heyday of GLP-1 drugs, an analyst said Tuesday after Pfizer stock surged on the results of its study in patients with diabetes. The post The Important — And Overlooked — Caveat Behind Pfi
3 Healthcare Trends to Ride for Longevity
05:21pm, Monday, 22'nd May 2023
Because of their longevity, predictability, and stability, healthcare trends can persist for years. The companies covered today are fundamentally and technically robust stocks currently taking advanta
Novo Nordisk says trial of oral weight-loss drug shows significant result
10:22am, Monday, 22'nd May 2023
Novo Nordisk's trial of the oral version of its weight-loss drug semaglutide has shown statistically significant and superior weight loss when compared to a placebo, the drugmaker said on Monday.
Obesity drug brings heart health benefit alongside weight loss- study
06:06pm, Friday, 19'th May 2023
Taking Novo Nordisk's new obesity drug may help reduce the risk of heart disease as well as boosting weight loss, according to new research from the United States.
Is Novo Nordisk Stock a Screaming Buy Right Now?
10:45am, Tuesday, 16'th May 2023
Novo Nordisk's rocket-fueled growth in type 2 diabetes and obesity treatment has made its stock a winning play for two straight years. With novel competitive threats starting to emerge, Novo's sky-hig
Don't Ignore the Momentum in These 3 Stocks
07:45pm, Monday, 15'th May 2023
Momentum investing is centered around targeting stocks displaying outperformance. And when you add in the Zacks Rank, the strategy can become even more potent.
Prescription-drug costs in spotlight as pharmacy benefit reform advances in Senate
02:46pm, Thursday, 11'th May 2023
A bipartisan effort to rein in prescription drug prices advanced Thursday as a key U.S. Senate committee approved a bill aimed at reforming pharmacy benefit managers.
Novo Nordisk (NVO) is an Incredible Growth Stock: 3 Reasons Why
02:26pm, Monday, 08'th May 2023
Novo Nordisk (NVO) possesses solid growth attributes, which could help it handily outperform the market.
Why Novo Nordisk Stock Is Marching Higher Today
12:54pm, Monday, 08'th May 2023
Last week, Novo's shares dipped on the news that it can't keep up with demand for its weight-loss medication Wegovy. Investors initially reacted poorly to this revelation due to a potential near-term
Buy These 4 Low-Beta Stocks to Endure Market Volatility
09:09am, Friday, 05'th May 2023
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Penumbra (PEN), Lamb Weston (LW), Transportadora (TGS) and Novo Nordisk (NVO) are poised to gain.
Why Novo Nordisk Stock Is Slumping Today
12:33pm, Thursday, 04'th May 2023
Danish pharma giant Novo Nordisk reported strong 2023 Q1 results today. Even so, the company announced plans to start rationing lower-strength starter doses of its popular weight-loss drug.
Novo Nordisk, A Top 1% Stock, Dives As Sales Of Obesity Blockbuster Drug Miss
10:44am, Thursday, 04'th May 2023
Novo Nordisk stock slumped Thursday after its weight loss blockbuster, Wegovy, missed sales expectations despite rocketing demand. The post Novo Nordisk, A Top 1% Stock, Dives As Sales Of Obesity Bloc
